Resources

Proteomics Databases



Metabolomics Databases

• • NGS Sequencing De Novo: When Short-Read Data Are Enough and When You Need a Hybrid Assembly Design

  Technical guide for NGS Sequencing De Novo: When Short-Read Data Are Enough and When You Need a Hybrid Assembly Design.

• • De Novo Sequencing by ESI-MS/MS: Troubleshooting Fragment Coverage and Sequence Ambiguity

  Technical guide for De Novo Sequencing by ESI-MS/MS: Troubleshooting Fragment Coverage and Sequence Ambiguity.

• • De Novo Assembly Shotgun Sequencing: What Affects Contig Quality, Repeat Resolution, and Assembly Usability

  Technical guide for De Novo Assembly Shotgun Sequencing: What Affects Contig Quality, Repeat Resolution, and Assembly Usability.

• • Protein Sequencing Service Cost Guide: Price, Timeline, and Deliverables

  Protein sequencing cost is shaped by more than the number of samples. A simple protein identification project from a clean gel band is very different from de novo sequencing of a low-abundance protein with no reliable database. A terminal residue check is different from a primary-structure evidence package for a biologic. The same keyword can describe very different scopes of work.

• • Antibody Sequencing Sample Problems and How to Avoid Failed Results

  Many sequencing failures begin before the instrument run. The sample may contain more than one antibody. The hybridoma may be unstable. RNA may be degraded. The antibody concentration may be lower than expected. Buffer additives may interfere with digestion, amplification, or downstream analysis. These issues do not always make sequencing impossible, but they can reduce coverage, increase ambiguity, and delay interpretation.

• • Antibody Sequencing Methods Compared: MS, PCR, and Edman

  Choosing a sequence recovery method is rarely a purely technical preference. It depends on the material available, the sequence information already known, and the decision the data must support. A hybridoma recovery project, a purified antibody rescue project, and a biosimilar characterization project can all involve sequencing, but they do not need the same workflow.

• • Antibody Sequencing: How It Works and When to Use It

  Antibody projects often reach a point where binding data alone is not enough. A monoclonal antibody may show strong activity in ELISA or cell assays, yet the team may not know the exact heavy-chain and light-chain sequences. A legacy hybridoma may lose productivity. A purified antibody may come from an old inventory with incomplete records. In each case, the sequence becomes the bridge between a useful binder and a reproducible research or development asset.

• • Antibody Sequencing Cost Guide: What Drives Price and Turnaround

  Project cost is shaped by more than the number of samples. A simple hybridoma sequence recovery project and a difficult de novo sequencing project from limited purified protein require different levels of preparation, instrumentation, assembly, and review. The same keyword can describe very different scopes of work.

• • De Novo Sequencing Proteomics: When to Use It for Novel Peptides, Sequence Gaps, and Unexpected Variants

  Technical guide for De Novo Sequencing Proteomics: When to Use It for Novel Peptides, Sequence Gaps, and Unexpected Variants.

• • How to Scope a Peptide De Novo Sequencing Project: Sample Type, Spectral Readiness, and Deliverable Planning

  Technical guide for How to Scope a Peptide De Novo Sequencing Project: Sample Type, Spectral Readiness, and Deliverable Planning.